B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crispr Therapeutics Ag (NQ: CRSP )

52.87 +2.40 (+4.76%)
Streaming Delayed Price Updated: 2:53 PM EST, Jan 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Crispr Therapeutics Ag

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
MaxCyte Inks Platform License With Vertex For Gene-Editing Program For Rare Blood Disorders
MaxCyte Inc (NASDAQ: MXCT) has signed a  
Via Benzinga
What Is Going on With Grom Social (GROM) Stock Today?
Grom Social (GROM) stock is heading higher on Tuesday following news of Chelsea and Matt Giegerich signing a deal with Curiosity Ink Media. 
Via InvestorPlace
Why Are Crypto Mining Stocks RIOT, MARA, HUT Up Today?
Crypto mining stocks are on the move Tuesday as investors react to Bitcoin (BTC) breaking past the $20,000 price point today! 
Via InvestorPlace
Why Is Crispr Therapeutics (CRSP) Stock Up Today?
Crispr Therapeutics (CRSP) stock is gaining on Tuesday after the FDA granted exagamglogene autotemcel (exa-cel) a rolling review. 
Via InvestorPlace
Crispr Stock Jumps After Unveiling Timeline For FDA Submission Of First-Ever CRISPR Drug
Crispr and Vertex nailed down the timeline for their blood diseases gene editor. 
Via Investor's Business Daily
Why CRISPR Therapeutics Stock Is Rising Today
CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher Tuesday after the company and Vertex Pharmaceuticals Inc (NASDAQ: VRTX) announced the U.S. 
Via Benzinga
Where CRISPR Therapeutics Stands With Analysts
CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings within the last quarter: 
Via Benzinga
S&P 500 Giant Leads 5 Stocks Showing Strength In Bear Market
Eli Lilly leads medical stocks setting up and showing relative strength. 
Via Investor's Business Daily
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,700 Today
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 20.85% on an annualized basis producing an average annual return of 29.91%. Currently, CRISPR Therapeutics has a... 
Via Benzinga
Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing
Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema. 
Via Investor's Business Daily
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why. 
Via Investor's Business Daily
Neurocrine Leads 5 Stocks To Watch In Sickly Market
Neurocrine Biosciences leads five medical stocks showing resilience. 
Via Investor's Business Daily
Here's How Much $100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 16.43% on an annualized basis producing an average annual return of 26.37%. Currently, CRISPR Therapeutics has a... 
Via Benzinga
5 Top Stocks Cathie Wood Is Selling This Week
Cathie Wood and her flagship ETF ARKK received $54.2 million of inflows earlier this month. Here's what she's selling. 
Via InvestorPlace
5 Cathie Wood Stocks Signaling “The Bear Market Is Over”
These top Cathie Wood stocks are signalling that the bear market is over. For savvy investors, that presents a chance to profit. 
Via InvestorPlace
Why This Analyst Sees A 51% Return On This Cathie Wood-Favored Biotech Stock
Biotech stocks have the potential for huge gains if a product or drug is deemed effective and safe, but investing in the shares of those companies can be volatile. 
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,900 Today
  CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 19.58% on an annualized basis producing an average annual return of 31.2%. Currently, CRISPR Therapeutics has a... 
Via Benzinga
Analysts See Softened Timelines For CRISPR Therapeutics' Sickle Cell Candidate In US
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2022
  
Via Benzinga
Karuna Therapeutics To $276? Plus SVB Leerink Almost Doubles Price Target On This Stock
Mizuho boosted the price target for Karuna Therapeutics, Inc. (NASDAQ: KRTX) from $190 to $276. Karuna Therapeutics shares fell 1.3% to $238.00 in pre-market trading. 
Via Benzinga
NVIDIA To $240? Here Are 5 Other Price Target Changes For Tuesday
Raymond James cut the price target on NVIDIA Corporation (NASDAQ: NVDA) from $250 to $240. Raymond James analyst Melissa Fairbanks maintained the stock with a Strong Buy. NVIDIA shares fell 2.8% to... 
Via Benzinga
Small Cap Biotechs Perk Up On Dealmaking
With M&A picking up we would think smaller deals make sense for large cap biopharma to expand pipelines and complement technology. 
Via Talk Markets
Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion
Shares of Pfizer's rumored takeover target have rocketed for two days running. 
Via Investor's Business Daily
Cathie Wood Sheds $5M In CRISPR Therapeutics, Scoops Up These Biotech Stocks Instead
Cathie Wood-led Ark Investment Management on Thursday sold 70,723 shares of gene editing company CRISPR Therapeutics AG (NASDAQ: CRSP), valued at over $5.58 million, via its flagship fund. 
Via Benzinga
Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today?
Gene editing stocks are a bright spot on the market today after Alnylam announced the success of one of its RNAi therapies, Patisiran. 
Via InvestorPlace
Will a Recession Cause a Housing Crash in 2022?
For stock investors looking for real estate exposure, the market dislocation also provides many once-a-decade deals. 
Via InvestorPlace
7 Undervalued Biotech Stocks to Buy Before They Boom
Despite recession fears, biological sciences will never go out of style, thus benefitting these undervalued biotech stocks to buy. 
Via InvestorPlace
Small Cap Biotech Stocks Are Trending Well
Despite a little weakness last week, small cap biotechs are trending well for traders. For investors entering the trade on July 5 all of our. focus stocks are up except ChemoCentryx. 
Via Talk Markets
Crispr Therapeutics Stock Shows Rising Price Performance With Jump To 94 RS Rating
Crispr Therapeutics sees its Relative Strength Rating enter the elite 90-plus level. 
Via Investor's Business Daily
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
The group has several commonalities, including strong ratings and promising charts. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.